User:Ivan E. Wang/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
Retinal pigment epithelium 65 (RPE65) also known as retinoid isomerohydrolase is a 65 kDa enzyme located within the human retinal pigment epithelium cells responsible for the chemical conversion of ''all-trans''-retinyl ester to ''11-cis''-retinol in the visual cycle.
Retinal pigment epithelium 65 (RPE65) also known as retinoid isomerohydrolase is a 65 kDa enzyme located within the human retinal pigment epithelium cells responsible for the chemical conversion of ''all-trans''-retinyl ester to ''11-cis''-retinol in the visual cycle.
-
(PLACEHOLDERThis is a default text for your page '''Ivan E. Wang/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
+
(PLACEHOLDER This is a default text for your page '''Ivan E. Wang/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.)
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.)
= Function =
= Function =
-
== Structural Features and Comparison of RPE65 with XXX ==
+
== Structural Features of RPE65 ==
-
== Structure alignment of RPE65 ==
 
== Enzymatic Catalyzed Reaction ==
== Enzymatic Catalyzed Reaction ==
 +
= Protein-Ligand Interaction =
= Protein-Ligand Interaction =
Line 18: Line 18:
== Exogenous Ligands ==
== Exogenous Ligands ==
 +
=== '''Emixustat (ACU-4429)''' ===
 +
Emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the development of emixustat as a potential inhibiter of RPE65. Currently emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD).
 +
Formulated as an hydrochloride salt, emixustat hydrochloride is taken by mouth and is known as a visual cycle modulator (VCM).
= Mutations =
= Mutations =

Revision as of 17:47, 28 January 2020

Retinal Pigment Epithelium 65 (Retinoid Isomerohydrolase)

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  2. Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644

Proteopedia Page Contributors and Editors (what is this?)

Ivan E. Wang

Personal tools